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of a primary non-small cell lung cancer and
synchronous carcinoma in situ in a medically
inoperable patient: case report
Feras Oskan1,2,4*, Christine Kornhuber1, Grit Krause3 and Dirk Vordermark1Abstract
The co-incidence of synchronous intraepithelial neoplasia and early stage invasive lung cancer is not a rare
phenomenon. The need for curative treatment and the invasive potential of squamous cell pulmonary carcinoma in
situ have been a topic of controversy. Surgical resection still remains the treatment of choice. Varieties of
endoscopic techniques such as brachytherapy were developed as an alternative to surgery in selected patients.
External beam radiation therapy has been used traditionally in combination with endobronchial brachytherapy in
the treatment of roentgenographically occult lung cancer, and can be offered for all patients, but is handicapped,
because these tumors are radiographically invisible. We report the first case of a pulmonary carcinoma in situ that
was successfully treated with stereotactic body radiation therapy.
Keywords: Pulmonary carcinoma in situ, Synchronous multiple lung cancer, Roentgenographically occult lung
cancer, Stereotactic body radiation therapy, Endoscopic intervention, Radiographic markerBackground
The co-incidence of synchronous intraepithelial neoplasia
and early stage lung cancer is not a rare phenomenon.
In-situ and early invasive lesions detectable only by bron-
choscopy have been referred to as roentgenologically oc-
cult lung cancer. A significant prevalence of synchronous
roentgenographically occult lung cancer as well as meta-
plasia and dysplasia was reported in surgical series of pa-
tients with resectable roentgenographically visible lung
cancer and estimated at 9% [1].
The need for curative treatment and the invasive po-
tential of squamous cell pulmonary carcinoma in situ
have been a topic of controversy [2,3]. Without thera-
peutic interventions, a progression of carcinoma in situ
into invasive cancer has been reported to occur in 21%
over 4–17 months [4]. Surgical resection still remains* Correspondence: Feras.oskan@uniklinikum-saarland.de
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reproduction in any medium, provided the orthe treatment of choice for roentgenographically occult
lung cancer providing survival rates of 96% and 94% at 5
and 10 years, respectively [5]. Nevertheless, patients with
primary lung cancers in two separate sites, where one
site represents roentgenographically occult cancer, and
the other site roentgenographically visible primary lung
cancer, might be medically inoperable or they refuse sur-
gery. For those patients, a variety of endoscopic tech-
niques could be offered as treatment options [2,3,6,7].
External beam radiation therapy [8] has traditionally
been used in combination with endobronchial brachy-
therapy in the treatment of roentgenographically occult
cancer, and been applied alone as an alternative to sur-
gery and endoscopic interventions [9].
We report on a case of synchronous pulmonary car-
cinoma in situ and roentgenographically visible early-
stage primary non-small-cell lung cancer in a medically
inoperable patient, where both lesions were treated sim-
ultaneously with hypofractionated stereotactic body radi-
ation therapy.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A 78-year-old Caucasian male patient was admitted to
our hospital in February 2011 for evaluation of an inci-
dental left lower lung mass, which was detected on chest
X-ray performed due to exacerbation of known GOLD
stage IV chronic obstructive pulmonary disease (COPD).
Chest computed tomography (CT) showed a 2.1 ×
2.6 cm sized mass in the left S6 segment with contact to
the pleura.
Flurdesoxyglucose whole-body positron emission tom-
ography (FDG-PET) demonstrated a pathologic intensive
glucose metabolism in the left lower lobe with standard-
ized uptake value (SUV) of 14.1; and much lower metab-
olism in the subcarinal, left mediastinal and right hilar
lymph nodes (SUV=2.7-3.3). No distant metastases were
observed. Magnetic resonance imaging of the skull re-
vealed no signs of brain metastasis. Transthoracic fine
needle aspiration was performed to confirm the malig-
nancy of the left lower lobe mass. This revealed moder-
ately differentiated, not otherwise specified, non-small
cell lung cancer.
Fiberrotic bronchoscopy demonstrated no abnormal
finding in the trachea and main bronchi. However, the
longitudinal mucosal folds were thickened at the orifice
of the right upper lobe bronchus, from which a tissue
sample was obtained. The pathology reports indicated a
squamous cell carcinoma in situ as well as fragments of
squamous dysplasia and metaplasia. To exclude the
malignancy in mediastinal and hilary lymph nodes,
transoesophageal endosonography was performed and
revealed several and enlarged lymph nodes in positions
7 and 4 L (up to 1.6 cm), from which specimens were
obtained. Cytologically as well as pathologically there
was no indication for malignancy in these lymph nodes.
The tumor was classified as cT2a cN0 cM0 with syn-
chronous carcinoma in situ (CIS).
Because of medical co-morbidities, poor performance
status, and compromised lunge function, stereotactic
body radiation therapy (SBRT) of the left lower lobe
mass and cryotherapy of the CIS disease in the right
upper main bronchus were recommended as the most
appropriate curative option by the multidisciplinary
team. In March 2011, the patient underwent a second
bronchoscopy to deliver cryotherapy of the known
lesions in the orifice of the right upper lobe main bron-
chus with 3 freeze cycles of 25 seconds each. There
was no post-procedural complication. However, during
bronchoscopy, a newly manifested thickness of sur-
rounding mucosa of the right segmental bronchus B1
was recognized. To prevent airways obstruction by the
necrotic tissue, second bronchoscopy was performed a
week later. It demonstrated further regression of the
granulation in the floor of right upper lobe bronchus,
but a widened bifurcation between the right B1 and B2bronchi. The pathological reports confirmed the persist-
ence and multifocality of carcinoma in situ.
After a second discussion of the case by the multidis-
ciplinary team, simultaneous SBRT of the carcinoma in
situ was planned at the same time with the SBRT of
the left lower lobe mass. Before SBRT treatment plan-
ning, the patient underwent bronchoscopy to place a
Visicoil (0.5×10 mm) fiducial marker per endobronchial
ultrasound-transbronchial aspiration (EBUS-TBNA) near
the lymph node station 11 R, since the placement of
Visicoil via EBUS in the area of the in situ lesions was
technically impossible [Figure 1].
Prior to radiation treatment, a dynamic planning CT
with three breathing phases was performed. The internal
target volume (ITV) was constructed by union of delin-
eations of the gross tumor volume (GTV) of the left
lower lobe mass in all breathing phases, and a margin of
5 mm in all directions was added to create the planning
target volume (PTV). A dose of 12.5 Gy × 3 fractions
was prescribed to the 65% isodose covering this PTV.
For carcinoma in situ disease there was no GTV to be
delineated, thus we pragmatically contoured an ellipsoid
as CTV that covered the right upper main bronchus and
the segmental bronchi B1/B2 cranially, ventrally and to
the right of the Visicoil marker. A margin of 5 mm in all
directions to account for the respiratory motion, which
was observed on planning CT, was added to create the
PTV. A dose of 10 Gy × 3 fractions was prescribed to
this PTV (65% isodose).
Multiple static beams with energies of 6 MV were used
[Figure 2, Figure 3] and the dose was delivered with daily,
CT-based image-guidance as well as MV-portal imaging,
using the radiographic marker to verify the treatment pos-
ition. The total dose was delivered in 10 days, with daily
sessions alternating between the two lesions.
At follow up in July 2011, a follow-up CT showed partial
remission in the left lower lobe mass, which was then
1.5 cm maximum diameter, and no evidence of pneumon-
itis. A scar of mucosa in the area of in situ carcinoma, but
no signs of new endobronchial manifestations were seen
at bronchoscopy. No biopsies were performed. The patient
reported no adverse advents of SBRT.
The patient refused further follow-up. Nonetheless, he
was admitted again to the hospital in April 2012 due to
exacerbation of COPD. A chest CT [Figure 4] showed no
change in size of the left lower lobe tumor and no signs
for nodal progression. The patient died in April 2012 due
to decompensation of cardiopulmonary function. No
endoscopic long-term follow-up data were available.
Discussion
External beam radiation therapy for carcinoma in situ is also
problematic, because these tumors are roentgenographically
invisible. It is, therefore, a challenging task for the radiation
Figure 1 Treatment planning computer tomography of carcinoma in situ. Planning CT shows the position of the Visicoil radiographic
marker in transversal, sagittal and coronal sections with respect to the right upper lobe main bronchus and demonstrates the ellipsoidal PTV with
respect to the Visicoil radiographic marker and the left upper lobe main bronchus in transversal, sagittal and coronal slices. Upper row: fast helical
scan of planning CT; lower row: slow helical high resolution scan acquired during verification procedure. Whereas in fast scanning mode almost
no motion of radiographic marker can be seen, breathing motion becomes apparent in slow helical scanning mode. For verification of correct
treatment position therefore the latter scanning mode was chosen. Radiographic marker movement center was found by means of a
3D-cursor (cross).
Figure 2 Radiation treatment planning of both lesions. Transversal, sagittal and coronal slices representative of SBRT isodose distribution for
carcinoma in situ (upper row) and for left lower lobe mass (lower row).
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Figure 3 Dose-constrains for both lesions. Dose volume histograms showing dosimetrical parameters analyzed including targets and organs
at risk.
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and in time, since there is no gross tumor volume (GTV) be
delineated. This inherent uncertainty of CTV must be ba-
lanced with the utilization of technological sophistication.
Due to the high efficacy in the treatment of superficial
lesions, high-dose brachytherapy could be a definitive
treatment for carcinoma in situ or endobronchial occult
lung cancer with limited invasion. Endobronchial ultra-
sonography has been reported to result in a change in
management in 36% of tumors thought to be curable by
endobronchial therapy after bronchoscopy [10].Figure 4 Follow-up CT after 12 month. Chest-CT one year after SBRT sho
changes in the right upper lobe (B).A recent large retrospective study [11] of 226 pa-
tients, of those 60 patients with carcinoma in situ,
treated with high-dose brachytherapy alone showed no
difference in local control between patients with in situ
carcinomas and those with invasive carcinomas, pro-
bably because they were classified as non-invasive on
biopsies though infiltrating on bronchoscopy. Further-
more, outcomes were worse for proximally located tu-
mors and in patients treated with one catheter. These
data suggest that the application of brachytherapy may
be limited by bronchoscopic access, proximal tumorwing the residual mass in the left lower lobe (A), and hypoventilation
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ment, geographic miss in dosimetric coverage of the
target volume when using one catheter, and by post-
procedural complications such as fatal hemoptysis or
fistula formation.
Compared with conventionally planned radiotherapy,
brachytherapy has the advantage of application of high-
dose irradiation in tumor with rapid dose reduction outside
the treatment volume. This favorable dosimetrical charac-
teristic can be emulated by stereotactic guidance of external
beam radiotherapy. The idea of use SBRT to deliver high-
dose-rate-like hypofractionated radiotherapy came origin-
ally from Molla et al. [12], who suggested a fractionated
stereotactic radiotherapy boost for gynecological tumors
as an alternative to high-dose brachytherapy and has re-
ceived some attention in recent years in the treatment of
cervical cancer [13]. We suggest that this idea could be
potentially adopted in the radiation therapy of roentgeno-
graphically occult lung cancer. There is growing evidence,
that it is possible to construct SBRT plans that closely
emulate high dose brachytherapy dosimetry and deliver
the plans non-invasively.
A major issue for the treatment of these lesions with
SBRT is, however, that high-dose delivery precision re-
quires a higher degree of accuracy in target volume de-
lineation and in patient set-up during the radiation
treatment course. Radiographic markers are well known
in the postoperative setting, where there is actually no
GTV to be delineated, and are standard tools for image-
guided radiotherapy (IGRT) and robotic radiosurgery,
and can be used for making invisible lesions “visible” for
guiding high-dose SBRT by target volume delineation
and positional verification.
In a prospective pilot series conducted by Malfiat et al.
[14] to assess the feasibility and safety of EZ-Clips HX
610–090 (Olympus, Aartselaar, Belgium) in inoperable pa-
tients with roentgenographically occult lung cancer, one
patients underwent high-dose external radiation therapy.
Two clips were used to delineate the clinical target volume
on the treatment planning system and to verify the correct
positioning of the patients during the treatment course. No
adverse events were observed. Both clips had disappeared,
one was already lost at the time of treatment planning, and
the other was lost during radiation treatment.
Anderson et al. [15] reported on the placement of 127 fi-
ducials in 32 patients with mediastinal and centrally located
thoracic tumors via flexible bronchoscopy as precursor to
robotic radiosurgery. Complications included migration
after insertion (one fiducial) and dropping in the airways
prior to insertion (24 fiducials). Of those, 18 were removed
with biopsy forceps, 2 were suctioned, 3 coughed out, and
2 were not retrieved, but were not seen on post-procedure
chest x-ray. Three fiducials in two patients embolized via
the pulmonary artery without adverse clinical consequence.Endoscopic Ultrasound-guided fiducials placement as
an alternative method has been described by Charabaty-
Pishvian et al. [16]. The Doppler function also verifies that
there are no interfering vessels between the tumor and the
needle, addressing the problem of post-procedural bleed-
ing and embolization via pulmonary artery. These pub-
lished data suggest that the implantation of radiographic
markers via flexible bronchoscopy or EBUS is safe, has no
clinically significant side adverse events, and can be of-
fered for most patients. Furthermore, the movement of
radiographic markers in space and time has been even
studied, and estimated to be clinically acceptable [17].
Nevertheless, high-dose radiation treatment for centrally
located tumors, particularly since the “bronchial exclusion
zone” of RTOG 0236 is the main location of roentgeno-
graphically occult lung cancer, remains the main issue
concerning the toxicity of SBRT. In addition to the frac-
tionation scheme, central location of target lesions also ap-
pears to be a predictor of normal tissue toxicity. However,
a recent review of 20 studies suggests that safe treatment
of central tumors can be achieved with hypofractionated
concepts with reduced single dose [18].
Conclusion
The implantation of radiographic marker near or in the
roentgenographically occult lung cancer appears to be safe
and would allow precise delivery of hypofractionated
SBRT to a target that is now radiologically visible and
trackable in space and in time.
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